Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson's disease

Ojeda-López, Carmen; Cervantes-Arriaga, Amin; Rodríguez-Violante, Mayela; Corona, Teresa
June 2013
Neurological Sciences;Jun2013, Vol. 34 Issue 6, p979
Academic Journal
The objective of this study is to assess the effect of smoking and caffeine intake in the dosage of dopaminergic replacement therapy. Patients were recruited from the movement disorders clinic of the National Institute of Neurology and Neurosurgery in Mexico City. An interviewer-administered structured questionnaire was given to all subjects regarding their smoking and caffeine drinking habits. Dopaminergic replacement therapy information was collected and levodopa, dopamine agonists, and levodopa equivalent daily doses were calculated. 146 Parkinson's disease patients (50 % female) were included. All patients were on antiparkinsonian treatment, with a mean levodopa equivalent daily dose (LEDD) of 550.2 ± 408. Patients were stratified according to smoking and caffeine drinking status. 104 (71.2 %) of the patients were 'never smokers', 33 (22.6 %) were 'former smokers' and 9 (6.2 %) were 'current smokers'. 40 (27.4 %) patients reported no history of caffeine intake, 36 (24.7 %) were former consumers and 70 (47.9 %) were current caffeine drinkers. No association between LEDD and smoking or caffeine intake was found. A weak positive correlation ( r = 0.22, p < 0.04) was found between the daily dose of pramipexole and the daily intake of caffeine. LEDD, levodopa daily dose and dopamine agonist daily dose were not related to smoking or caffeine intake status. We found a weak correlation between caffeine daily intake and pramipexole dose. Further prospective exploration is needed to address the interaction of concomitant A2A antagonism induced by caffeine intake and dopaminergic replacement therapy.


Related Articles

  • Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Thanvi, Bhomraj; Lo, Nelson; Robinson, Tom // Postgraduate Medical Journal;Jun2007, Vol. 83 Issue 980, p384 

    Levodopa is the most effective drug for treating Parkinson's disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa...

  • Which drugs work best for early Parkinson's disease? Jam, Liza; Benko, Rebecca; Safranek, Sarah // Journal of Family Practice;Feb2012, Vol. 61 Issue 2, p106 

    The article discusses two medications in treating early Parkinson's disease. It mentions the use of Levodopa/carbidopa as medication for Parkinson's disease, but may result on the occurrence of dyskinesia and dystonia. It also cites the use of bromocriptine, a dopamine agonist for treating...

  • Management. Williams, Adrian; Willmot, Mark // GP: General Practitioner;11/2/2007, p31 

    The article presents information on the treatment of Parkinson's disease. It is stated that Levodopa is the most effective parkinsonism drug but is associated with motor fluctuations and dyskinesias after a few years. However, its early use is recommended in older patients as they are less prone...

  • Parkinson's. Portyansky, Elena // Drug Topics;5/3/99, Vol. 143 Issue 9, p39 

    Focuses on treatment options for the degenerative neurologic disorder known as Parkinson's disease. Neuroprotective therapy; Treatment guidelines; Pharmacist counseling for patients; Advantages of dopamine agonists over levodopa therapy.

  • Study supports first-line use of ropinirole for early PD.  // Formulary;Sep99, Vol. 34 Issue 9, p733 

    Reports on the findings that provide evidence for treating early-stage Parkinson's disease (PD) with a dopamine agonist and initiating levodopa only after PD symptoms. Comparison of a dopamine agonist with levodopa; Association with less risk of dyskinesias; Ropinirole as a first-line option...

  • ‘Don’t delay, start today’: delaying levodopa does not delay motor complications. Fox, Susan H.; Lang, Anthony E. // Brain: A Journal of Neurology;Oct2014, Vol. 137 Issue 10, p2628 

    This scientific commentary refers to ‘The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa’, by Cilia et al. (doi:10.1093/brain/awu195).

  • Clinical Pharmacology of Dopamine Agonists in Parkinson's Disease. Lange, K.W. // Drugs & Aging;1998, Vol. 13 Issue 5, p381 

    Oral levodopa is the most effective symptomatic treatment for Parkinson's disease. Dopamine agonists are useful adjuvants to levodopa in the pharmacotherapy of parkinsonian patients. Monotherapy with dopamine agonists in early Parkinson's disease has been advocated in order to delay the...

  • What is the best initial treatment of Parkinson's disease? Schreck, Jennifer; Kelsberg, Gary; Rich, Joanne // Journal of Family Practice;Nov2003, Vol. 52 Issue 11, p897 

    There are no studies clearly demonstrating the best initial treatment for Parkinson's disease in the United States. A systematic review of randomized control trials recommends that drug choices should be based on each patient's individual symptoms and response to medication. In 2002, the...

  • Factores asociados con la selección de pramipexol de liberación prolongada versus liberación inmediata en pacientes con enfermedad de Parkinson. Cervantes-Arriaga, Amin; Rodríguez-Violante, Mayela; López-Ruiz, Minerva; Estrada-Bellmann, Ingrid; Zúñiga-Ramírez, Carlos; Otero-Cerdeira, Elisa; Camacho-Ordóñez, Azyadeh; González-Latapi, Paulina; Morales-Briceño, Hugo; Martínez-Ramírez, Daniel // Revista Mexicana de Neurociencia;Mar/Apr2013, Vol. 14 Issue 2, p76 

    Introduction: Pramipexole is a dopamine agonist effective to treat the motor symptoms of Parkinson disease available as immediate or extended release. Objective: The aim of this study is to determine whether there are differences in the profile of patients receiving pramipexole according to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics